Psychological Problems in Pregnancy and the Postnatal Period

Author(s):  
Sujatha Thamban ◽  
Quazi Selina Naquib
2014 ◽  
Vol 7 (4) ◽  
pp. 156-159 ◽  
Author(s):  
Aine Gallagher ◽  
Jonathan O’B Hourihane ◽  
Louise C Kenny ◽  
Alan D Irvine ◽  
Ali S Khashan

Background It is unknown whether skin’s barrier function changes in pregnancy. Trans Epidermal Water Loss (TEWL) refers to the total amount of water loss through the skin and TEWL can be measured non-invasively as an index of skin barrier function. We measured TEWL during and after pregnancy to evaluate pregnancy-related skin barrier function. Methods This was a prospective, longitudinal cohort study of 52 low-risk, first-time pregnant women nested within the Screening for Pregnancy Endpoints (SCOPE) Ireland study. TEWL (gwater/m2/h) was measured three times during pregnancy: 19–21 weeks, 27–32 weeks and 36 weeks; and three times postnatally: 2–4 days, 2 months and 6 months post-delivery. Data were analysed using SPSS 18.0 and P > 0.05 was considered statistically significant. Results A rise in TEWL was seen between each visit with the highest readings, exceeding the normal range of 0–20 gwater/m2/h, recorded at two months post-delivery. Forty women attended at two months post-delivery of whom 22 women had an average reading between 0 and 20 gwater/m2/h; 10 women had an average reading between 21 and 40 gwater/m2/h and 8 women had an average reading between 41 and 75 gwater/m2/h. Readings had returned to an average of 0–20 gwater/m2/h at six months postnatally. Conclusion TEWL increases slightly in pregnancy and the postnatal period. The clinical significance of this is unclear and requires further investigation.


1991 ◽  
Vol 29 (13) ◽  
pp. 49-50

Between 1940 and 1970, up to 10000 women in England and Wales, and up to 2 million in the USA, received prophylactic diethylstilboestrol (DES) in an attempt to improve the outcome of pregnancy. Trials performed only later showed that DES did not reduce the incidence of abortion, toxaemia, prematurity or perinatal mortality.1 However, the use of DES in pregnancy is now known to damage the fetal reproductive tract: it can cause malignancy, maldevelopment of the urogenital tract, infertility, increased perinatal mortality and psychological problems. The complex issues raised by this disaster are not just historical, but still affect people now and have important lessons for the future.2


2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Amanda Bye ◽  
Jill Shawe ◽  
Debra Bick ◽  
Abigail Easter ◽  
Megan Kash-Macdonald ◽  
...  

2006 ◽  
Vol 36 (12) ◽  
pp. 1663-1670 ◽  
Author(s):  
MARIE-PAULE AUSTIN

Recent pharmaceutical company and regulatory body circulars warning against the use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy have left clinicians in somewhat of a quandary as to how to manage their more severely depressed patients in pregnancy. Conversely, up to 75% of depressed women ceasing their antidepressants periconceptually will relapse. Studies reporting on adverse neonatal outcomes following exposure to SSRIs in the latter half of pregnancy suggest that the fetus is exposed to significant concentrations of these medications during this time. Adverse neonatal effects affecting the respiratory, gastrointestinal and neurological systems are, however, predominantly mild and self-limiting. One small retrospective case study suggests that SSRI exposure in the latter half of pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the neonate (PPHN), however, the absolute risk of developing PPHN remains very small and these findings will require replication with a prospective study. While the studies to date suggest the need to closely monitor SSRI-exposed neonates in the immediate postnatal period, preferably with a neonatal withdrawal scale and access to neonatology services, there is currently no clear argument for women to be weaned off their SSRI in late pregnancy. The decision to use SSRIs at this time will have to be made on a case-by-case basis in close consultation with the mother and her partner.


2006 ◽  
Vol 40 (8) ◽  
pp. 704-711 ◽  
Author(s):  
Sarah L. Roberts ◽  
Sarah L. Roberts ◽  
John A. Bushnell ◽  
Sarah L. Roberts ◽  
John A. Bushnell ◽  
...  

Objective: To compare the psychological health of men with partners who have postpartum depression (PPD; index group) with that of men with partners without PPD (comparison group). Method: Using a cross-sectional survey, psychological symptoms and disturbances of index group men (n = 58) and comparison group men (n = 116) were compared. Validated self-report measures were used to assess five key areas of mental health: depression, anxiety, non-specific psychological impairment, aggression and alcohol use. Results: Index group men had more symptoms of depression, aggression and nonspecific psychological impairment, and had higher rates of depressive disorder, nonspecific psychological problems and problem fatigue than comparison group men. Index group men were also more likely to have three or more comorbid psychological disturbances. There was no difference between the groups on measures of anxiety and alcohol use. Conclusions: Although many men in the postnatal period experience a variety of mental health problems, those who have a partner with PPD are themselves at increased risk for experiencing psychological symptoms and disturbances. Differentiation of psychological syndromes is important; higher rates of depressive disorder, non-specific psychological problems and problem fatigue were found, but rates of anxiety disorder and hazardous alcohol use did not differ between the groups. More attention from health professionals to men's mental health in the postnatal period may be beneficial to the entire family system.


2018 ◽  
Vol 21 (4) ◽  
pp. 411-419 ◽  
Author(s):  
Gretchen Bandoli ◽  
Grace M. Kuo ◽  
Renu Sugathan ◽  
Christina D. Chambers ◽  
Matthieu Rolland ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document